RESHAPE LIFESCIENCES INC (RSLS)
US76090R2004 - Common Stock
We assign a fundamental rating of 3 out of 10 to RSLS. RSLS was compared to 196 industry peers in the Health Care Equipment & Supplies industry. The financial health of RSLS is average, but there are quite some concerns on its profitability. While showing a medium growth rate, RSLS is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year RSLS has reported negative net income.
RSLS had a negative operating cash flow in the past year.
RSLS had negative earnings in each of the past 5 years.
RSLS had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
RSLS's Return On Assets of -106.71% is on the low side compared to the rest of the industry. RSLS is outperformed by 82.14% of its industry peers.
RSLS's Return On Equity of -170.76% is on the low side compared to the rest of the industry. RSLS is outperformed by 78.06% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -106.71% | ||
| ROE | -170.76% | ||
| ROIC | N/A |
ROA(3y)-213.94%
ROA(5y)-174.81%
ROE(3y)-525.31%
ROE(5y)-397.87%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
RSLS has a better Gross Margin (63.83%) than 64.29% of its industry peers.
In the last couple of years the Gross Margin of RSLS has grown nicely.
RSLS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 63.83% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.57%
GM growth 5Y9.59%
2. Health
2.1 Basic Checks
RSLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RSLS has more shares outstanding
The number of shares outstanding for RSLS has been increased compared to 5 years ago.
There is no outstanding debt for RSLS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
RSLS has an Altman-Z score of -85.83. This is a bad value and indicates that RSLS is not financially healthy and even has some risk of bankruptcy.
RSLS has a worse Altman-Z score (-85.83) than 94.90% of its industry peers.
RSLS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -85.83 |
ROIC/WACCN/A
WACC9.92%
2.3 Liquidity
A Current Ratio of 2.73 indicates that RSLS has no problem at all paying its short term obligations.
RSLS's Current ratio of 2.73 is in line compared to the rest of the industry. RSLS outperforms 42.35% of its industry peers.
RSLS has a Quick Ratio of 1.74. This is a normal value and indicates that RSLS is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.74, RSLS is not doing good in the industry: 63.78% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.73 | ||
| Quick Ratio | 1.74 |
3. Growth
3.1 Past
RSLS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 96.31%, which is quite impressive.
Looking at the last year, RSLS shows a very negative growth in Revenue. The Revenue has decreased by -22.76% in the last year.
The Revenue has been decreasing by -0.95% on average over the past years.
EPS 1Y (TTM)96.31%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q99.67%
Revenue 1Y (TTM)-22.76%
Revenue growth 3Y76.07%
Revenue growth 5Y-0.95%
Revenue growth Q2Q-36.27%
3.2 Future
The Earnings Per Share is expected to grow by 38.07% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 16.06% on average over the next years. This is quite good.
EPS Next Y88.28%
EPS Next 2Y38.07%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year12.24%
Revenue Next 2Y16.06%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for RSLS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RSLS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as RSLS's earnings are expected to grow with 38.07% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.07%
EPS Next 3YN/A
5. Dividend
5.1 Amount
RSLS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
RESHAPE LIFESCIENCES INC
NASDAQ:RSLS (4/19/2024, 7:14:21 PM)
After market: 0.17 +0 (+2.84%)0.1653
-0.01 (-3.16%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap3.88M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -106.71% | ||
| ROE | -170.76% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 63.83% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.81
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.73 | ||
| Quick Ratio | 1.74 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)96.31%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y88.28%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-22.76%
Revenue growth 3Y76.07%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y